Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Trial to Assess the Efficacy and Safety of Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus

NCT06719024 is registered in ClinicalTrials.gov with Hospital Authority, Hong Kong as lead sponsor.

NCT NCT06719024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06719024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Trial to Assess the Efficacy and Safety of Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus
Lead sponsor
Hospital Authority, Hong Kong
Phase
Phase 2/3
Overall status
Recruiting
Start date
November 29, 2024
Completion date
January 30, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vitiligo